261280523 Stock Overview
A biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
PharmaEssentia Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$18.60 |
| 52 Week High | NT$0 |
| 52 Week Low | NT$0 |
| Beta | 0.57 |
| 1 Month Change | 5.08% |
| 3 Month Change | -7.00% |
| 1 Year Change | 65.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 35.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 261280523 | LU Biotechs | LU Market | |
|---|---|---|---|
| 7D | 4.5% | -0.5% | 0.1% |
| 1Y | 65.1% | 10.4% | -5.0% |
Return vs Industry: 261280523 exceeded the Luxembourg Biotechs industry which returned 11.8% over the past year.
Return vs Market: 261280523 exceeded the Luxembourg Market which returned -6% over the past year.
Price Volatility
| 261280523 volatility | |
|---|---|
| 261280523 Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in LU Market | 6.8% |
| 10% least volatile stocks in LU Market | 3.3% |
Stable Share Price: 261280523 has not had significant price volatility in the past 3 months compared to the Luxembourg market.
Volatility Over Time: 261280523's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Ko-Chung Lin | www.pharmaessentia.com |
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia.
PharmaEssentia Corporation Fundamentals Summary
| 261280523 fundamental statistics | |
|---|---|
| Market cap | US$6.16b |
| Earnings (TTM) | US$56.47m |
| Revenue (TTM) | US$254.54m |
109.1x
P/E Ratio24.2x
P/S RatioIs 261280523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 261280523 income statement (TTM) | |
|---|---|
| Revenue | NT$8.32b |
| Cost of Revenue | NT$1.07b |
| Gross Profit | NT$7.25b |
| Other Expenses | NT$5.40b |
| Earnings | NT$1.85b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.55 |
| Gross Margin | 87.10% |
| Net Profit Margin | 22.19% |
| Debt/Equity Ratio | 0.3% |
How did 261280523 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 05:18 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PharmaEssentia Corporation is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pinghan Hsieh | Capital Securities Corporation |
| Wangbin Zhou | Citigroup Inc |
| Hsuan Chen | KGI Securities Co. Ltd. |